Everything below concerns lipodystrophy. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-03-30. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
=== Skin and circulation === Rattlesnakes, like other members of the Squamata order, have a circulatory system that is powered by a three-chambered heart composed of two atria and one ventricle. The right atrium receives deoxygenated blood from veins coming from the systemic circuit. The left atrium receives oxygenated blood from the lungs in the pulmonary circuit and pumps it to the ventricle and through the systemic circuit via capillaries and arteries. Rattlesnake skin has a set of overlapping scales that cover the entire body, providing protection from a variety of threats, including dehydration and physical trauma. The typical rattlesnake, genus Crotalus, has the top of its head covered with small scales, except, with a few species, a few crowded plates directly over the snout. The skin of snakes is highly sensitive to contact, tension, and pressure; they are capable of feeling pain. An important function of the skin is the sensation of changes in air temperature, which can guide the snakes towards warm basking/shelter locations. All snakes are ectotherms. To maintain a stable body temperature, they exchange heat with their external environments. Snakes often move into open, sunny areas to absorb heat from the sun and warmed earth, a behavior known as basking. Nerves in the skin regulate the flow of blood into the veins near the surface. The skin of rattlesnakes is intricately patterned in a manner that camouflages them from their predators.
=== Industrial synthesis === The industrial synthesis of pantothenic acid starts with the aldol condensation of isobutyraldehyde and formaldehyde. The resulting hydroxypivaldehyde is converted to its cyanohydrin derivative. which is cyclised to give racemic pantolactone. This sequence of reactions was first published in 1904.
==== In water ==== Cyanobacteria possess carboxysomes, which increase the concentration of CO2 around RuBisCO to increase the rate of photosynthesis. An enzyme, carbonic anhydrase, located within the carboxysome, releases CO2 from dissolved hydrocarbonate ions (HCO−3). Before the CO2 can diffuse out, RuBisCO concentrated within the carboxysome quickly sponges it up. HCO−3 ions are made from CO2 outside the cell by another carbonic anhydrase and are actively pumped into the cell by a membrane protein. They cannot cross the membrane as they are charged, and within the cytosol they turn back into CO2 very slowly without the help of carbonic anhydrase. This causes the HCO−3 ions to accumulate within the cell from where they diffuse into the carboxysomes. Pyrenoids in algae and hornworts also act to concentrate CO2 around RuBisCO.
Sources: en.wikipedia.org
Targeted mass spectrometry is a mass spectrometry technique that uses multiple stages of tandem mass spectrometry (MSn with n=2 or 3) for ions of specific mass (m/z), at specific time. The values of the m/z and time are defined in an inclusion list which is derived from a previous analysis.
=== Pharmacodynamics === DMPEA shows weak affinity for serotonin receptors. It induces the head-twitch response, a behavioral proxy of serotonergic psychedelic effects, in rodents. DMPEA has some activity as a monoamine oxidase inhibitor.
Agribusiness Arla Foods (dairy) Dansk Landbrugs Grovvareselskab (DLG) (agricultural coop (Danish a.m.b.a.). Main focus is agricultural supply and trade) Danish Crown (meat products) Banking Danske Bank (commercial banking and mortgage lending) Nordea Nykredit Jyske Bank Saxo Bank Sydbank Clothing and attire ECCO (shoe and leather accessories manufacturer and retailer) Bestseller Construction FLSmidth (global supplier of equipment and services to the cement and minerals industries) Rockwool (mineral wool producer with production in 28 countries) Velux (windows and skylights production, owned by Villum Foundation) Rambøll COWI Energy technology Vestas (wind turbines) Siemens Wind Power (wind turbines) Danfoss (climate and energy) Grundfos (the world's largest pump manufacturer) NKT A/S (Power cables and subsea umbilicals) Ørsted (company) (Formerly known as DONG energy) Electronics Linak Bang and Olufsen (hi-fi equipment) Nilfisk Ortofon Danfoss Food and drink Carlsberg (brewing company) Royal Unibrew Novonesis (food ingredients and enzymes) Danisco (enzymes, biotechnology and pharmaceutical supplier) Insurance Alm. Brand Tryg Medical equipment Widex William Demant Pharmaceutical and biotechnology Many of the largest food producers are also engaged in biotechnology and research. Notable companies dedicated to the pharmaceutical and biotechnology sector, includes:
Sources: en.wikipedia.org
More than 30 signs and symptoms are variably associated with Marfan syndrome. The most prominent of these affect the skeletal, cardiovascular, and ocular systems, but all fibrous connective tissue throughout the body can be affected.
=== Magnetophoresis === One application for microfluidic devices is the separation and sorting of different fluids or cell types. Microfluidic devices have been integrated with magnetophoresis: the migration of particles by a magnetic field. This can be accomplished by sending a fluid containing at least one magnetic component through a microfluidic channel that has a magnet positioned along the length of the channel. This creates a magnetic field inside the microfluidic channel which draws magnetically active substances towards it, effectively separating the magnetic and non-magnetic components of the fluid. This technique can be readily utilized in industrial settings where the fluid at hand already contains magnetically active material. For example, a handful of metallic impurities can find their way into certain consumable liquids, namely milk and other dairy products. Conveniently, in the case of milk, many of these metal contaminants exhibit paramagnetism. Therefore, before packaging, milk can be flowed through channels with magnetic gradients as a means of purifying out the metal contaminants. cell separations are of interest in microfluidics. This is accomplished. First, a paramagnetic substance (usually micro/nanoparticles or a paramagnetic fluid) needs to be functionalized to target the cell type of interest. This can be accomplished by identifying a transmembranal protein unique to the cell type of interest and subsequently functionalizing magnetic particles with the complementary antigen or antibody.
=== Malaria === A number of different proteins on the surface of Plasmodium falciparum malaria parasites help the invaders bind to red blood cells. But once attached to host blood cells, the parasites need to shed the 'sticky' surface proteins that would otherwise interfere with entrance into the cell. The Sheddase enzyme, specifically called PfSUB2 in this example, is required for the parasites to invade cells; without it, the parasites die. The sheddase is stored in and released from cellular compartments near the tip of the parasite, according to the study. Once on the surface, the enzyme attaches to a motor that shuttles it from front to back, liberating the sticky surface proteins. With these proteins removed, the parasite gains entrance into a red blood cell. The entire invasion lasts about 30 seconds and without this ADAM metallopeptidase, malaria would be ineffective at invading the red blood cells.
=== 2010s and 2020s === Wolverine joined the Avengers and appeared as a regular character throughout the Avengers (2010–2013) and New Avengers (2010–2013) series, both written by Brian Michael Bendis. Jason Aaron wrote a fourth volume of Wolverine that began in August 2010 and lasted 40 issues. Aaron also wrote a new X-Men storyline, X-Men: Schism (2011), in which Wolverine and Cyclops come into conflict, dividing the team. The same year, he began writing Wolverine and the X-Men, in which Wolverine becomes the headmaster of the Jean Grey School for Higher Learning and must mentor a younger generation of mutants as well as leading one of the X-Men teams. In the Avengers vs. X-Men storyline of 2012, Wolverine sides with the Avengers against his previous team. In 2013, a fifth volume of Wolverine began, written by Paul Cornell and Alan Davis and lasted 13 issues. Cornell then collaborated with Ryan Stegman on Wolverine volume 6 (February 2014 - February 2015). In 2014, Charles Soule wrote the "Death of Wolverine" storyline, in which Wolverine contracts a virus that disables his healing factor, allowing his enemies to finally kill him. He is resurrected in 2018, in the Return of Wolverine miniseries. 2019 saw the beginning of a new era for the X-Men, spearheaded by Jonathan Hickman, starting with the House of X and Powers of X series. This launched the "Krakoan Age", with mutants founding a new nation on the living island of Krakoa, where they are capable of regularly resurrecting mutants after their death.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
It is a synthetic peptide analog of human growth hormone-releasing hormone. It is used clinically to reduce excess visceral abdominal fat in adults with HIV-associated lipodystrophy. It works by stimulating pituitary growth hormone release.